List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1183842/publications.pdf Version: 2024-02-01

		30070	27406
296	14,485	54	106
papers	citations	h-index	g-index
311	311	311	24636
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Nutritional parameters associated with prognosis in non-critically ill hospitalized COVID-19 patients: The NUTRI-COVID19 study. Clinical Nutrition, 2022, 41, 2980-2987.	5.0	13
2	Men with COVID-19 die. Women survive. Maturitas, 2022, 158, 34-36.	2.4	9
3	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. Genes and Immunity, 2022, 23, 51-56.	4.1	41
4	Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection. Diagnostics, 2022, 12, 14.	2.6	3
5	A Multi-Stage Optimisation Approach to Design Relocation Strategies in One-Way Car-Sharing Systems With Stackable Cars. IEEE Transactions on Intelligent Transportation Systems, 2022, 23, 17048-17061.	8.0	6
6	Reliable data delivery in ICN-IoT environments. Future Generation Computer Systems, 2022, 134, 271-286.	7.5	5
7	Towards end-to-end application slicing in Multi-access Edge Computing systems: Architecture discussion and proof-of-concept. Future Generation Computer Systems, 2022, 136, 110-127.	7.5	7
8	SLICES, a scientific instrument for the networking community. Computer Communications, 2022, 193, 189-203.	5.1	4
9	Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy. Internal and Emergency Medicine, 2021, 16, 1141-1152.	2.0	8
10	Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival. British Journal of Haematology, 2021, 192, 11-12.	2.5	0
11	Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing?. Digestive and Liver Disease, 2021, 53, 456-460.	0.9	1
12	Low risk of SARS-CoV-2 transmission by fomites in real-life conditions. Lancet Infectious Diseases, The, 2021, 21, e112.	9.1	138
13	Unique immunological profile in patients with COVID-19. Cellular and Molecular Immunology, 2021, 18, 604-612.	10.5	181
14	COVID-19 and breast cancer: may the microbiome be the issue?. Future Oncology, 2021, 17, 123-126.	2.4	8
15	Vitamin D 250H deficiency in COVID-19 patients admitted to a tertiary referral hospital. Clinical Nutrition, 2021, 40, 2469-2472.	5.0	68
16	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCVâ€infected patients treated in a realâ€life setting. Journal of Viral Hepatitis, 2021, 28, 558-568.	2.0	3
17	Endovascular Surgery during COVID-19 Virus Pandemic as a Valid Alternative to Open Surgery. Annals of Vascular Surgery, 2021, 71, 101-102.	0.9	6
18	Acute deep vein thrombosis in COVID 19 hospitalized patients. Risk factors and clinical outcomes. Phlebology, 2021, 36, 240-242.	1.2	6

#	Article	IF	CITATIONS
19	Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use. PLoS ONE, 2021, 16, e0245281.	2.5	25
20	Cerebral Toxocariasis as a Cause of Epilepsy: A Pediatric Case. Neuropediatrics, 2021, 52, 142-145.	0.6	2
21	Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE). Scientific Reports, 2021, 11, 1137.	3.3	22
22	Acute Thrombosis of Lower Limbs Arteries in the Acute Phase and After Recovery From COVID19. Annals of Surgery, 2021, 273, e159-e160.	4.2	19
23	Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19. Blood Advances, 2021, 5, 662-673.	5.2	42
24	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. International Journal of Infectious Diseases, 2021, 104, 315-319.	3.3	66
25	Persistence of SARS-CoV-2-specific B and TÂcell responses in convalescent COVID-19 patients 6–8Âmonths after the infection. Med, 2021, 2, 281-295.e4.	4.4	153
26	Lung ultrasound presentation of COVID-19 patients: phenotypes and correlations. Internal and Emergency Medicine, 2021, 16, 1317-1327.	2.0	18
27	Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: A SITA GIOVANI-IRENE promoted web-survey. Respiratory Medicine, 2021, 179, 106341.	2.9	2
28	Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Nature Medicine, 2021, 27, 993-998.	30.7	161
29	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.9	2
30	Can Alveolar-Arterial Difference and Lung Ultrasound Help the Clinical Decision Making in Patients with COVID-19?. Diagnostics, 2021, 11, 761.	2.6	7
31	Mutational and immunogenetic landscape of <scp>HCV</scp> â€associated Bâ€cell lymphoproliferative disorders. American Journal of Hematology, 2021, 96, E210-E214.	4.1	7
32	Application-aware resource allocation and data management for MEC-assisted IoT service providers. Journal of Network and Computer Applications, 2021, 181, 103020.	9.1	16
33	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. Open Forum Infectious Diseases, 2021, 8, ofab278.	0.9	31
34	Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons?. Future Oncology, 2021, 17, 1577-1580.	2.4	5
35	Re: "Endothelitis in COVID-19-Positive Patients after Extremity Amputation for Acute Thrombotic Events― Annals of Vascular Surgery, 2021, 73, e6-e7.	0.9	12
36	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. Digestive and Liver Disease, 2021, 53, 677-681.	0.9	13

#	Article	IF	CITATIONS
37	An Integrated Optimisation-Simulation Framework for Scalable Smart Charging and Relocation of Shared Autonomous Electric Vehicles. Energies, 2021, 14, 3633.	3.1	13
38	Are people previously infected with SARS-CoV-2 likely to experience COVID-19 symptoms again after vaccination? Results from an Italian COVID-19 referral center. Human Vaccines and Immunotherapeutics, 2021, , 1-2.	3.3	1
39	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. Frontiers in Medicine, 2021, 8, 639970.	2.6	20
40	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. Journal of Healthcare Engineering, 2021, 2021, 1-10.	1.9	2
41	SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by exÂvivo ELISpot assay. Clinical Microbiology and Infection, 2021, 27, 1029-1034.	6.0	49
42	Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 547-554.	1.6	1
43	Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting. Leukemia and Lymphoma, 2021, 62, 3311-3312.	1.3	0
44	Impact of Pneumococcal Urinary Antigen Testing in COVID-19 Patients: Outcomes from the San Matteo COVID-19 Registry (SMACORE). Journal of Personalized Medicine, 2021, 11, 762.	2.5	2
45	A simple prognostic score for COVID-19 hospitalized patients developing deep vein thrombosis. Phlebology, 2021, 36, 026835552110300.	1.2	1
46	Cutaneous lymphocytic vasculitis after administration of COVID â€19 mRNA vaccine. Dermatologic Therapy, 2021, 34, e15076.	1.7	17
47	COVID vaccination and asthma exacerbation: might there be a link?. International Journal of Infectious Diseases, 2021, 112, 243-246.	3.3	21
48	What prompts clinicians to start antibiotic treatment in COVID-19 patients? An Italian web survey helps us to understand where the doubts lie. Journal of Global Antimicrobial Resistance, 2021, 26, 74-76.	2.2	6
49	Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2021, 53, 1089-1104.	0.9	10
50	HBV and HDV: New Treatments on the Horizon. Journal of Clinical Medicine, 2021, 10, 4054.	2.4	4
51	Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill Patients with SARS-CoV2 Pneumonia. Blood Purification, 2021, 50, 566-571.	1.8	49
52	Characterizing the Genomic Profile in High-Grade Gliomas: From Tumor Core to Peritumoral Brain Zone, Passing through Glioma-Derived Tumorspheres. Biology, 2021, 10, 1157.	2.8	9
53	High Frequencies of Functional Virus-Specific CD4+ T Cells in SARS-CoV-2 Subjects With Olfactory and Taste Disorders. Frontiers in Immunology, 2021, 12, 748881.	4.8	11
54	The early phase of the COVID-19 epidemic in Lombardy, Italy. Epidemics, 2021, 37, 100528.	3.0	158

#	Article	IF	CITATIONS
55	CovidDeep: SARS-CoV-2/COVID-19 Test Based on Wearable Medical Sensors and Efficient Neural Networks. IEEE Transactions on Consumer Electronics, 2021, 67, 244-256.	3.6	39
56	The use of intrahepatic portosystemic shunt in HIV positive patients: A retrospective multicentric study. Digestive and Liver Disease, 2020, 52, 355-357.	0.9	0
57	Interferon-free compared to interferon-based antiviralÂregimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia, 2020, 34, 1462-1466.	7.2	30
58	Running out of bullets: The challenging management of acute hepatitis and SARSâ€COVâ€2 from the SMatteo COvid19 Registry (SMACORE). Liver International, 2020, 40, 2655-2659.	3.9	7
59	Edge-centric resource allocation for heterogeneous IoT applications using a CoAP-based broker. International Journal of Cloud Computing, 2020, 9, 28.	0.3	2
60	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	2.6	137
61	Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica, 2020, 105, 2834-2840.	3.5	114
62	SARS-CoV-2 Virologic and Immunologic Correlates in Patients with Olfactory and Taste Disorders. Microorganisms, 2020, 8, 1052.	3.6	5
63	Ultrastructural Evidence of Direct Viral Damage to the Olfactory Complex in Patients Testing Positive for SARS-CoV-2. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 972.	2.2	38
64	2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Medicine, 2020, 21, 617-624.	2.2	115
65	Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. Internal and Emergency Medicine, 2020, 15, 1457-1465.	2.0	32
66	Acute arterial and deep venous thromboembolism in COVID-19 patients: Risk factors and personalized therapy. Surgery, 2020, 168, 987-992.	1.9	43
67	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. European Journal of Internal Medicine, 2020, 82, 38-47.	2.2	88
68	Directâ€acting antiviral agents in lymphoproliferative disorders: more complex than expected. British Journal of Haematology, 2020, 191, 661-662.	2.5	0
69	Detection of the SARS oVâ€2 in different biologic specimens from positive patients with COVIDâ€19, in Northern Italy. Pediatric Allergy and Immunology, 2020, 31, 72-74.	2.6	4
70	Edge-Assisted Resource Management for Data-Centric IoT Applications in Shared Sensor Networks. , 2020, , .		1
71	Our recommendations for acute management of COVID-19. Critical Care, 2020, 24, 207.	5.8	21
72	Radiographic findings in 240 patients with COVID-19 pneumonia: time-dependence after the onset of symptoms. European Radiology, 2020, 30, 6161-6169.	4.5	93

#	Article	IF	CITATIONS
73	Circulating endothelial cells in <scp>COVID</scp> â€19. American Journal of Hematology, 2020, 95, E187-E188.	4.1	28
74	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 2020, 8, 695.	3.6	186
75	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine, 2020, 383, 1827-1837.	27.0	1,152
76	Emergency Department and Out-of-Hospital Emergency System (112—AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. Internal and Emergency Medicine, 2020, 15, 825-833.	2.0	50
77	Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. Journal of Hospital Infection, 2020, 105, 474-476.	2.9	51
78	Performance of VivaDiag COVIDâ€19 IgM/IgG Rapid Test is inadequate for diagnosis of COVIDâ€19 in acute patients referring to emergency room department. Journal of Medical Virology, 2020, 92, 1724-1727.	5.0	205
79	SARS Cov-2 infection in a renal-transplanted patient: A case report. American Journal of Transplantation, 2020, 20, 1882-1884.	4.7	76
80	Myocarditis in a 16-year-old boy positive for SARS-CoV-2. Lancet, The, 2020, 395, e116.	13.7	52
81	SARS-CoV-2 positivity in rectal swabs: implication for possible transmission. Journal of Global Antimicrobial Resistance, 2020, 22, 754-755.	2.2	9
82	HCV infection and non-Hodgkin lymphomas: an evolving story. Clinical and Experimental Medicine, 2020, 20, 321-328.	3.6	13
83	Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement. Journal of Antimicrobial Chemotherapy, 2020, 75, 1354-1356.	3.0	1
84	Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 2122-2128.	1.3	15
85	Myocardial localization of coronavirus in COVIDâ€19 cardiogenic shock. European Journal of Heart Failure, 2020, 22, 911-915.	7.1	783
86	Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared pragmatic protocol. Nutrition, 2020, 74, 110835.	2.4	206
87	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents. JAMA Pediatrics, 2020, 174, 882.	6.2	898
88	Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. Nature Medicine, 2020, 26, 855-860.	30.7	1,373
89	PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment?. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 97-101.	3.3	12
90	Setup of a Dedicated Coronavirus Intensive Care Unit. Anesthesiology, 2020, 133, 244-246.	2.5	11

#	Article	IF	CITATIONS
91	Late-onset cutaneous eruption in hospitalized COVID-19 patients. European Journal of Dermatology, 2020, 30, 621-622.	0.6	2
92	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Eurosurveillance, 2020, 25, .	7.0	119
93	Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Eurosurveillance, 2020, 25, .	7.0	158
94	QoS-Aware Data Management Mechanisms for Optimal Resource Utilisation in Crowd-Assisted Shared Sensor Networks. , 2020, , .		1
95	BDP-CoAP: Leveraging Bandwidth-Delay Product for Congestion Control in CoAP. , 2019, , .		13
96	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	3.7	341
97	The Possible Role of Gut Microbiota and Microbial Translocation Profiling During Chemo-Free Treatment of Lymphoid Malignancies. International Journal of Molecular Sciences, 2019, 20, 1748.	4.1	2
98	RE: Effects of Long-Term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology, 2019, 156, 2352-2353.	1.3	2
99	Weak signals in the mobility landscape: car sharing in ten European cities. EPJ Data Science, 2019, 8, .	2.8	17
100	Prophylaxis of spontaneous bacterial peritonitis: Is there still room for quinolones?. Journal of Hepatology, 2019, 70, 1027-1028.	3.7	5
101	The impact of HIV infection and men who have sex with men status on hepatitis A infection: The experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009â€2016 period. Journal of Viral Hepatitis, 2019, 26, 761-765.	2.0	7
102	A Performance Model for Single Charger Multi-Socket Charging Stations in Shared Mobility Systems. , 2019, , .		3
103	Cascaded Model Predictive Control for Shared Autonomous Electric Vehicles Systems with V2G Capabilities. , 2019, , .		10
104	Real life experiences in HCV management in 2018. Expert Review of Anti-Infective Therapy, 2019, 17, 117-128.	4.4	8
105	AISF position paper on HCV in immunocompromised patients. Digestive and Liver Disease, 2019, 51, 10-23.	0.9	5
106	Human-centric Data Dissemination in the IoP. ACM Transactions on Autonomous and Adaptive Systems, 2019, 14, 1-25.	0.8	10
107	User-Based Relocation of Stackable Car Sharing. Communications in Computer and Information Science, 2019, , 256-273.	0.5	Ο
108	Highlights of the 2017 European <scp>AIDS</scp> Clinical Society (EACS) Guidelines for the treatment of adult <scp>HIV</scp> â€positive persons version 9.0. HIV Medicine, 2018, 19, 309-315.	2.2	77

#	Article	IF	CITATIONS
109	Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2018, 16, 1153-1162.e7.	4.4	90
110	Making opportunistic networks in IoT environments CCN-ready: A performance evaluation of the MobCCN protocol. Computer Communications, 2018, 123, 81-96.	5.1	12
111	Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases. Infection, 2018, 46, 183-188.	4.7	7
112	Impact of <scp>HBV</scp> and S. mansoni on portal pressure: Synergy or innocent bystanders?. Liver International, 2018, 38, 377-377.	3.9	0
113	Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). Seminars in Oncology, 2018, 45, 259-263.	2.2	2
114	Editorial: microbial translocation and immune activation profiling during treatment of chronic HCV. Alimentary Pharmacology and Therapeutics, 2018, 48, 1320-1321.	3.7	0
115	Design and Implementation of a COAP-Based Broker for Heterogeneous M2M Applications. , 2018, , .		1
116	Design and Evaluation of a Rate-Based Congestion Control Mechanism in CoAP for IoT Applications. , 2018, , .		12
117	RTT-Based Congestion Control for the Internet of Things. Lecture Notes in Computer Science, 2018, , 3-15.	1.3	4
118	Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS ONE, 2018, 13, e0192627.	2.5	6
119	Antibiotic stewardship and empirical antibiotic treatment: How can they get along?. Digestive and Liver Disease, 2017, 49, 579-584.	0.9	10
120	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Digestive and Liver Disease, 2017, 49, 731-741.	0.9	19
121	Cutaneous septic emboli from <i>Candida glabrata</i> in a haematological patient. American Journal of Hematology, 2017, 92, 1111-1112.	4.1	Ο
122	Directâ€acting antivirals during or after immunochemotherapy in hepatitis C virus–positive diffuse large Bâ€cell lymphomas. Hepatology, 2017, 66, 1341-1343.	7.3	11
123	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	8.1	15
124	A reinforcement learning-based link quality estimation strategy for RPL and its impact on topology management. Computer Communications, 2017, 112, 1-13.	5.1	51
125	Consensus conference on TIPS management: Techniques, indications, contraindications. Digestive and Liver Disease, 2017, 49, 121-137.	0.9	111
126	Adherence to a lifestyle programme in overweight/obese pregnant women and effect on gestational diabetes mellitus: a randomized controlled trial. Maternal and Child Nutrition, 2017, 13, .	3.0	64

#	Article	IF	CITATIONS
127	Relocation in car sharing systems with shared stackable vehicles: Modelling challenges and outlook. , 2017, , .		7
128	Stackable vs autonomous cars for shared mobility systems: A preliminary performance evaluation. , 2017, , .		5
129	A Generic Software Framework for Carsharing Modelling Based on a Large-Scale Multi-agent Traffic Simulation Platform. Lecture Notes in Computer Science, 2017, , 88-111.	1.3	6
130	On the Performance of a One-way Car Sharing System in Suburban Areas: A Real-world Use Case. , 2017, , .		5
131	Beyond the gut bacterial microbiota: The gut virome. Journal of Medical Virology, 2016, 88, 1467-1472.	5.0	71
132	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood, 2016, 128, 2527-2532.	1.4	149
133	The impact of regulated electric fleets on the power grid: The car sharing case. , 2016, , .		11
134	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. Clinical Infectious Diseases, 2016, 64, ciw846.	5.8	8
135	Interplay of Link Quality Estimation and RPL Performance. , 2016, , .		9
136	Optimal deployment of stations for a car sharing system with stochastic demands: A queueing theoretical perspective. , 2016, , .		15
137	A machine-learned ranking algorithm for dynamic and personalised car pooling services. , 2016, , .		5
138	Acupressure on Self-Reported Sleep Quality During Pregnancy. JAMS Journal of Acupuncture and Meridian Studies, 2016, 9, 11-15.	0.7	6
139	Characterising demand and usage patterns in a large station-based car sharing system. , 2016, , .		27
140	Experimental set-up of DC PEV charging station supported by open and interoperable communication technologies. , 2016, , .		7
141	Mobile edge clouds for Information-Centric IoT services. , 2016, , .		28
142	Optimal charging of electric vehicle fleets for a car sharing system with power sharing. , 2016, , .		17
143	Emerging biological agents for hepatitis C. Expert Opinion on Emerging Drugs, 2016, 21, 219-224.	2.4	2
144	273: A customized low glycaemic-index (GI) diet prevents both the gestational diabetes mellitus (GDM) and the large forÂgestational age (LGA) babies in overweight/obese pregnant women. American Journal of Obstetrics and Gynecology, 2016, 214, S159.	1.3	0

#	Article	IF	CITATIONS
145	AISF position paper on liver disease and pregnancy. Digestive and Liver Disease, 2016, 48, 120-137.	0.9	32
146	Next generation IEEE 802.11 Wireless Local Area Networks: Current status, future directions and open challenges. Computer Communications, 2016, 75, 1-25.	5.1	82
147	The societal burden of chronic liver diseases: results from the COME study. BMJ Open Gastroenterology, 2015, 2, e000025.	2.7	38
148	<scp>OPERA</scp> : responses to peginterferon and ribavirin therapy in a subgroup of interferonâ€naÃ⁻ve patients with <scp>HIV</scp> / <scp>HCV</scp> genotype 2/3 coâ€infection in Italy. Liver International, 2015, 35, 120-129.	3.9	4
149	Liver transplantation for hepatitis C virus in the era of direct-acting antiviral agents. Current Opinion in HIV and AIDS, 2015, 10, 361-368.	3.8	3
150	Workshop program (SmartVehicles 2015). , 2015, , .		0
151	Offloading cellular traffic with opportunistic networks: a feasibility study. , 2015, , .		5
152	A joint multicast/D2D learning-based approach to LTE traffic offloading. Computer Communications, 2015, 72, 26-37.	5.1	20
153	Cellular traffic offloading via opportunistic networking with reinforcement learning. Computer Communications, 2015, 71, 129-141.	5.1	18
154	Epidemiological characteristics of bloodstream infections in patients with different degrees of liver disease. Infection, 2015, 43, 561-567.	4.7	17
155	Development and persistence of DAA resistance associated mutations in patients failing HCV treatment. Journal of Clinical Virology, 2015, 72, 114-118.	3.1	15
156	Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals?. Journal of Hepatology, 2015, 63, 1294.	3.7	4
157	Analysis of MAC-level throughput in LTE systems with link rate adaptation and HARQ protocols. , 2015, , .		12
158	Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection. Digestive and Liver Disease, 2015, 47, 218-225.	0.9	35
159	Data Offloading Techniques in Cellular Networks: A Survey. IEEE Communications Surveys and Tutorials, 2015, 17, 580-603.	39.4	291
160	Efficient data collection in multimedia vehicular sensing platforms. Pervasive and Mobile Computing, 2015, 16, 78-95.	3.3	8
161	Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. Thrombosis and Haemostasis, 2014, 111, 1067-1076.	3.4	6
162	Using electric vehicles to improve building energy sustainability. , 2014, , .		3

#	Article	IF	CITATIONS
163	EnergyTest: A tool for assessing building energy sustainability. , 2014, , .		3
164	Robust Adaptive Modulation and Coding (AMC) Selection in LTE Systems Using Reinforcement Learning. , 2014, , .		22
165	Assessing the effect of introducing adaptive charging stations in public EV charging infrastructures. , 2014, , .		4
166	Offloading through Opportunistic Networks with Dynamic Content Requests. , 2014, , .		5
167	Management of infections in cirrhotic patients: Report of a Consensus Conference. Digestive and Liver Disease, 2014, 46, 204-212.	0.9	40
168	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2014, 59, 1692-1705.	7.3	75
169	Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference. Journal of Hepatology, 2014, 60, 1075-1089.	3.7	77
170	Trickle-L ² : Lightweight link quality estimation through Trickle in RPL networks. , 2014, , .		15
171	Adaptive data offloading in opportunistic networks through an actor-critic learning method. , 2014, , .		12
172	Reliable Data Delivery With the IETF Routing Protocol for Low-Power and Lossy Networks. IEEE Transactions on Industrial Informatics, 2014, 10, 1864-1877.	11.3	79
173	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2014, 46, 936-942.	0.9	17
174	Smoothing peak demands through aggregate control of background electrical loads. , 2014, , .		6
175	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2014, 46, 18-24.	0.9	9
176	Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV–HIV Coinfection in Interferon-Naive Patients. Antiviral Therapy, 2014, 19, 735-745.	1.0	5
177	Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. Critical Reviews in Oncology/Hematology, 2013, 87, 12-27.	4.4	19
178	On the interplay between RPL and address autoconfiguration protocols in LLNs. , 2013, , .		4
179	Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naA ⁻ ve patients. Virology Journal, 2013, 10, 355.	3.4	78
180	The role of communication systems in smart grids: Architectures, technical solutions and research challenges. Computer Communications, 2013, 36, 1665-1697.	5.1	277

#	Article	IF	CITATIONS
181	Policies for efficient usage of an EV charging infrastructure deployed in city parking facilities. , 2013, ,		7
182	The role of the RPL routing protocol for smart grid communications. , 2013, 51, 75-83.		125
183	Human immunodeficiency virus and hepatitis c virus coinfection: The agenda is full while waiting for new drugs. Hepatology, 2013, 57, 4-6.	7.3	2
184	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 712-723.	0.9	155
185	Designing and Evaluating Activity-Based Electric Vehicle Charging in Urban Areas. , 2013, , .		18
186	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. Journal of Hepatology, 2013, 59, 658-666.	3.7	41
187	Errors in ribosomal sequence datasets generated using PCR-coupled â€~panbacterial' pyrosequencing, and the establishment of an improved approach. Molecular and Cellular Probes, 2013, 27, 65-67.	2.1	9
188	Robust and efficient data collection schemes for vehicular multimedia sensor Networks. , 2013, , .		19
189	Portal Hypertension in Childhood Bilateral Wilms' Tumor Survivor: An Excellent Indication for TIPS. Case Reports in Gastrointestinal Medicine, 2013, 2013, 1-3.	0.3	0
190	Using vehicular networks for urban surveillance: An adaptive data collection scheme. , 2013, , .		1
191	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology, 2013, 57, 1046-1054.	7.3	89
192	An analytical model for content dissemination in opportunistic networks using cognitive heuristics. , 2012, , .		14
193	Effective management of a public charging infrastructure through a smart management system for electric vehicles. , 2012, , .		7
194	Message from the workshops chairs. , 2012, , .		0
195	Forecast model for the evaluation of economic resources employed in the health care of patients with HIV infection. ClinicoEconomics and Outcomes Research, 2012, 4, 117.	1.9	Ο
196	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2012, 56, 850-860.	7.3	97
197	Spatial and Temporal Dynamics of Hepatitis B Virus D Genotype in Europe and the Mediterranean Basin. PLoS ONE, 2012, 7, e37198.	2.5	55
198	RELADO. International Journal of Adaptive Resilient and Autonomic Systems, 2012, 3, 54-71.	0.3	0

#	Article	IF	CITATIONS
199	Will direct-acting antivirals make a difference in HIV–HCV coinfected patients?. Expert Review of Anti-Infective Therapy, 2011, 9, 699-701.	4.4	0
200	Performance analysis of 802.11-based Internet access for highways with multiclass traffic flows. , 2011, , .		1
201	Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C. Digestive and Liver Disease, 2011, 43, 337-344.	0.9	7
202	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. Digestive and Liver Disease, 2011, 43, 259-265.	0.9	29
203	Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection. Digestive and Liver Disease, 2011, 43, 575-578.	0.9	12
204	An efficient routing protocol for point-to-point elastic traffic in wireless mesh networks. , 2011, , .		2
205	Hepatocellular carcinoma in HIV hepatitis C virus. Current Opinion in HIV and AIDS, 2011, 6, 534-538.	3.8	19
206	The 3rd IEEE international Workshop on Hot Topics in Mesh Networking HotMESH 2011. , 2011, , .		0
207	The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver International, 2011, 31, 66-74.	3.9	32
208	Routing Internet traffic in heterogeneous mesh networks: Analysis and algorithms. Performance Evaluation, 2011, 68, 841-858.	1.2	8
209	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmunity Reviews, 2011, 10, 444-454.	5.8	186
210	Load-aware routing in mesh networks: Models, algorithms and experimentation. Computer Communications, 2011, 34, 948-961.	5.1	19
211	A self-adaptive routing paradigm for wireless mesh networks based on reinforcement learning. , 2011, ,		7
212	Regression of Indolent B-Cell Lymphoma After Lamivudine Prophylaxis of Hepatitis B Virus Infection. Journal of Clinical Oncology, 2011, 29, e543-e545.	1.6	4
213	Throughput and Fairness Analysis of 802.11-Based Vehicle-to-Infrastructure Data Transfers. , 2011, , .		12
214	TALB: A Traffic-Aware Load Balancer for Throughput Improvement in Wireless Mesh Networks. , 2011, , .		4
215	Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. Gut, 2011, 60, 1023-1023.	12.1	9
216	Genetic Variation in IL28B and Treatment-induced Clearance of Hepatitis C Virus in HIV-Positive Patients With Acute and Chronic Hepatitis C. Journal of Infectious Diseases, 2011, 203, 595-601.	4.0	55

#	Article	IF	CITATIONS
217	Predictors of Sustained Virological Response After Antiviral Therapy for Chronic Hepatitis C In Patients with Hemophilia: The Role of the Interleukin-28B (IL28B) Polymorphism. Blood, 2011, 118, 2276-2276.	1.4	0
218	Impact of treatmentâ€related liver toxicity on the outcome of HCVâ€positive nonâ€Hodgkin's lymphomas. American Journal of Hematology, 2010, 85, 46-50.	4.1	52
219	Survey on diversity-based routing in wireless mesh networks: Challenges and solutions. Computer Communications, 2010, 33, 269-282.	5.1	56
220	Computer Communications: Introduction to the Special Section on Hot Topics in Mesh Networking. Computer Communications, 2010, 33, 897.	5.1	0
221	Automatically configured, optimised and QoS aware wireless mesh networks. , 2010, , .		2
222	gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut, 2010, 59, 513-520.	12.1	124
223	MaxOPP: A novel Opportunistic Routing for wireless mesh networks. , 2010, , .		13
224	Opportunistic packet scheduling and routing in wireless mesh networks. , 2010, , .		6
225	Load-balanced routing and gateway selection in wireless mesh networks: Design, implementation and experimentation. , 2010, , .		15
226	A framework for opportunistic routing in multi-hop wireless networks. , 2010, , .		9
227	Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas. Current Clinical Pharmacology, 2010, 5, 74-81.	0.6	24
228	Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection. International Journal of Cancer, 2009, 124, 2246-2249.	5.1	8
229	Design and performance evaluation of throughput-aware rate adaptation protocols for IEEE 802.11 wireless networks. Performance Evaluation, 2009, 66, 811-825.	1.2	17
230	Dynamic address autoconfiguration in hybrid ad hoc networks. Pervasive and Mobile Computing, 2009, 5, 300-317.	3.3	25
231	Capacity-aware routing in heterogeneous mesh networks. , 2009, , .		12
232	Route selection for capacity maximization in multi-rate TDMA-based wireless ad hoc networks. , 2009, ,		1
233	A queuing modeling approach for Load-Aware Route Selection in heterogeneous mesh networks. , 2009, , .		15
234	A framework for adaptive opportunistic forwarding in wireless networks. , 2009, , .		0

#	Article	IF	CITATIONS
235	Average-value analysis of 802.11 WLANs with persistent TCP flows. IEEE Communications Letters, 2009, 13, 218-220.	4.1	6
236	An accurate closed-form formula for the throughput of long-lived TCP connections in IEEE 802.11 WLANs. Computer Networks, 2008, 52, 199-212.	5.1	12
237	Different evolutionary rates and epidemic growth of hepatitis B virus genotypes A and D. Virology, 2008, 380, 84-90.	2.4	38
238	Spontaneous Hepatitis C Virus Clearance in HIVâ€Infected Patients: New Insights for Improving Management. Journal of Infectious Diseases, 2008, 198, 1262-1264.	4.0	2
239	Throughput Analysis and Measurements in IEEE 802.11 WLANs with TCP and UDP Traffic Flows. IEEE Transactions on Mobile Computing, 2008, 7, 171-186.	5.8	62
240	Experimentation and performance evaluation of rate adaptation algorithms in wireless mesh networks. , 2008, , .		23
241	Design and Implementation of an Enhanced 802.11 MAC Architecture for Single-Hop Wireless Networks. Eurasip Journal on Wireless Communications and Networking, 2007, 2007, 1.	2.4	2
242	Could Tenofovir Modify the Model End-Stage Liver Disease (MELD) Score in Patients With End-Stage Liver Disease Eligible for Liver Transplantation?. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 123.	2.1	3
243	A Layer-2 Framework for Interconnecting Ad Hoc Networks to Fixed Internet: Test-bed Implementation and Experimental Evaluation. Computer Journal, 2007, 50, 478-499.	2.4	3
244	Natural History of Compensated Viral Cirrhosis in a Cohort of Patients With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 297-303.	2.1	26
245	Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology, 2007, 46, 1016-1025.	7.3	35
246	High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology, 2007, 365, 113-124.	2.4	64
247	Design of an enhanced access point to optimize TCP performance in Wi-Fi hotspot networks. Wireless Networks, 2007, 13, 259-274.	3.0	11
248	Natural history of chronic hepatitis B in co-infected patients. Journal of Hepatology, 2006, 44, S65-S70.	3.7	198
249	Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. Journal of Hepatology, 2006, 44, S146-S150.	3.7	33
250	Message from the Workshop Co-Organizers. , 2006, , .		0
251	Assessment of Procedure Tolerability During Her Option Endometrial Ablation in Out-Patient Settings*. Obstetrics and Gynecology, 2006, 107, 58S-59S.	2.4	0
252	Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. Aids, 2006, 20, 1951-1954.	2.2	64

#	Article	IF	CITATIONS
253	Performance modelling and measurements of TCP transfer throughput in 802.11-based WLAN. , 2006, , .		15
254	Broadband Wireless Access Networks: A Roadmap on Emerging Trends and Standards. , 2005, , 215-240.		26
255	Mesh networks: commodity multihop ad hoc networks. , 2005, 43, 123-131.		676
256	Hepatotoxicity and Nelfinavir: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2005, 3, 482-488.	4.4	10
257	Dissociation of Serum and Liver Hepatitis C Virus RNA Levels in Patients Coinfected with Human Immunodeficiency Virus and Treated with Antiretroviral Drugs. Journal of Clinical Microbiology, 2004, 42, 3012-3016.	3.9	5
258	Comments on the review â€~Care of patients with hepatitis C and HIV co-infection' by Soriano et al Aids, 2004, 18, 2101-2102.	2.2	0
259	Hepatocellular carcinoma in HIV-infected patients. Aids, 2004, 18, 2285-2293.	2.2	213
260	Comparison of IFN-α2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a. Aids, 2004, 18, 1080-1082.	2.2	0
261	Comparative Performance Evaluation of Scatternet Formation Protocols for Networks of Bluetooth Devices. Wireless Networks, 2004, 10, 197-213.	3.0	47
262	Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis. Journal of Hepatology, 2004, 40, 501-506.	3.7	46
263	Analytical Modeling of TCP Clients in Wi-Fi Hot Spot Networks. Lecture Notes in Computer Science, 2004, , 626-637.	1.3	19
264	Hepatitis B virus genotype distribution in HIV-1 coinfected patients. Gastroenterology, 2003, 125, 1559-1560.	1.3	19
265	Optimal capacity of p-persistent CSMA protocols. IEEE Communications Letters, 2003, 7, 139-141.	4.1	55
266	The Pavia consensus statement. Aids, 2003, 17, S170-S179.	2.2	44
267	Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart. Aids, 2003, 17, S83-S87.	2.2	20
268	Design and Analysis of a Bluetooth-Based Indoor Localization System. Lecture Notes in Computer Science, 2003, , 711-725.	1.3	66
269	Hypertension among HIV patients. Journal of Hypertension, 2003, 21, 1377-1382.	0.5	161
270	Rapid hepatitis B virus-DNA decay in co-infected HIV–hepatitis B virus â€~e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. Aids, 2003, 17, 783-784.	2.2	27

#	Article	IF	CITATIONS
271	Hcv Chronic Hepatitis in Patients With Hiv: Clinical Management Issues. American Journal of Gastroenterology, 2002, 97, 1598-1606.	0.4	25
272	Prevalence of Metabolic Syndrome Among HIV Patients. Diabetes Care, 2002, 25, 1253-1254.	8.6	81
273	Hepatocellular Carcinoma in HIV-Infected Patients With Chronic Hepatitis: An Emerging Issue. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 535-536.	2.1	11
274	High Prevalence of Metabolic Syndrome Among HIV–Infected Patients: Link With the Cardiovascular Risk. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 363-365.	2.1	41
275	Optimization of efficiency and energy consumption in p-persistent CSMA-based wireless LANs. IEEE Transactions on Mobile Computing, 2002, 1, 10-31.	5.8	126
276	Prevalence of wild-type in interferon sensitivity determining region (ISDR) of hepatitis C virus in HIV-1 positive patients infected with HCV genotype 3A non responders to anti-HCV treatment. Journal of Hepatology, 2002, 36, 71.	3.7	0
277	Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C. BMC Infectious Diseases, 2002, 2, 17.	2.9	1
278	Mitochondrial toxicity in HIV-HCV coinfection: It depends on the choice of antiretroviral drugs?. Hepatology, 2002, 35, 500-501.	7.3	13
279	Distinct Mutational Drug Resistance Profiles of HIV-1 RNA in Plasma and Culture Isolates of Patients Receiving Antiretroviral Therapy. Intervirology, 2002, 45, 52-55.	2.8	3
280	Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice and Once Daily Administration in Patients with HIV. Clinical Pharmacokinetics, 2001, 40, 695-700.	3.5	42
281	YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology, 2001, 121, 1027-1028.	1.3	36
282	Hepatitis C virus RNA dynamics during antiretroviral therapy. Blood, 2001, 97, 3318-3319.	1.4	5
283	A simple protocol for the dynamic tuning of the backoff mechanism in IEEE 802.11 networks. Computer Networks, 2001, 37, 33-44.	5.1	30
284	Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 114-123.	2.1	79
285	Quantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapy. International Journal of Infectious Diseases, 2000, 4, 187-193.	3.3	10
286	Health-Related Quality of Life in Asymptomatic Patients with HIV. Pharmacoeconomics, 2000, 18, 63-72.	3.3	34
287	Daily Interferon Regimen for Chronic Hepatitis C. Clinical Drug Investigation, 1999, 18, 11-16.	2.2	8
288	HIV Type 1 Intraperitoneal Infection of Rabbits Permits Early Detection of Serum Antibodies to Gag, Pol, and Env Proteins, Neutralizing Antibodies, and Proviral DNA from Peripheral Blood Mononuclear Cells. AIDS Research and Human Retroviruses, 1995, 11, 287-296.	1.1	5

#	Article	IF	CITATIONS
289	Estimation of token bucket parameters of VoIP traffic. , 0, , .		10
290	Performance evaluation of a new scatternet formation protocol for multi-hop Bluetooth networks. , 0, , .		14
291	IEEE 802.11 optimal performances: RTS/CTS mechanism vs. basic access. , 0, , .		32
292	A performance comparison of scatternet formation protocols for networks of Bluetooth devices. , 0, , .		30
293	Throughput vs. temporal fair MAC protocols in multi-rate WLANs: Analysis and performance evaluation. , 0, , .		4
294	A Novel Fair Medium Access Control for 802.11-based Multi-Hop Ad hoc Networks. , 0, , .		3
295	Throughput Analysis of UDP and TCP Flows in IEEE 802.11b WLANs: A Simple Model and Its Validation. , 0, , ,		10
296	Distributed Contention Control in Heterogeneous 802.11b WLANs. , 0, , .		4